Suramin - PaxMedica
Alternative Names: IV suramin; PAX-101; PAX-102Latest Information Update: 26 Apr 2024
At a glance
- Originator PaxMedica
- Class Antiprotozoals; Behavioural disorder therapies; Naphthalenesulfonates
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III African trypanosomiasis
- Phase II Pervasive child development disorders
- Preclinical Fragile X tremor ataxia syndrome; Unspecified
Most Recent Events
- 23 Apr 2024 PaxMedica plans to provide emergency access to Suramin for African trypanosomiasis in Malawi in next 30 days
- 16 Apr 2024 PaxMedica receives emergency request from African Health Ministry for Suramin (IV) in African trypanosomiasis
- 11 Apr 2024 PaxMedica plans to launch Suramin for African trypanosomiasis in USA